Plant-based Vaccines Market New Research On Industry Growth 2018| With Pharmaceutical Companies: Medicago, Mitsubishi Tanabe Pharma, iBio, Fraunhofer Center for Molecular Biotechnology (CMB), Protalix BioTherapeutics

Coherent Market Insights has announced the addition of the “Plant-based Vaccines Market Size Status and Forecast 2026”, The report classifies the global Plant-based Vaccines Market in a precise manner to offer detailed insights about the aspects responsible for augmenting as well as restraining market growth.

This report studies the global Plant-based Vaccines Speaker market, analyzes and researches the Plant-based Vaccines Speaker development status and forecast in North America, Europe, Asia Pacific, Latin America and Rest of the World. This report focuses on the top players in global market, like Medicago, Mitsubishi Tanabe Pharma, iBio, Fraunhofer Center for Molecular Biotechnology (CMB), Protalix BioTherapeutics

Request a sample copy : https://www.coherentmarketinsights.com/insight/request-sample/2004

Increasing number of research and development activities by key players in the market and robust pipeline of plant-based vaccines is expected to be a major factor driving the global plant-based vaccines market growth during the forecast period. For instance, in 2017, Medicago Inc.—a Canada-based biopharmaceutical company that focuses on development of plant-based vaccines—initiated phase 3 clinical trial to evaluate efficacy of its seasonal quadrivalent influenza vaccine (QIV) candidate. The trial comprises around 10,000 subjects in the following countries: the U.S., Canada, Germany, the U.K., the Philippines, Finland, and Thailand. QIV was developed using a new virus-like particle (VLP) technology, which is an alternative to egg-based and cell-based production systems.

High prevalence of viruses such as Influenza, Zika virus, and Ebola is expected to increase demand for plant-based vaccines, which in turn is expected to propel growth of the plant-based vaccines market. For instance, according to a report published by Centers for Disease Control and Prevention (CDC), in October 2016, around 140,000 to 710,000 influenza related patients were hospitalized and around 12,000 to 56,000 influenza related deaths were registered, since 2010.

Furthermore, in 2017, researchers from the Arizona State University (ASU), in the U.S., developed the first plant-based Zika vaccine. According to the university, the newly developed plant-based Zika vaccine is safer, potent, and its production cost is much cheaper. Such robust pipeline of plant-based vaccines is expected to be a major factor in growth of the global plant-based vaccines market during the forecast period. Moreover, various government initiatives for development of plant-based vaccines are also expected to fuel the plant-based vaccines market growth during the forecast period. For instance, in 2015, Public Health Agency of Canada (PHAC) granted a contract to Medicago Inc. for development of two plant-based vaccines for Sudan strain of Ebola virus.

By Vaccine Type

Bacterial Vaccines
Viral Vaccines
Parasite Vaccines
Others

By Application

Influenza
Zika Virus
Ebola Virus
Others

By Geography

North America
Latin America
Europe
Asia Pacific
Middle East
Africa

North America is expected to be dominant in the global plant vaccines market over the forecast period. This is owing to high prevalence of infectious disease such as Ebola and Influenza in the region. For instance, according to a study by Influenza Research Center, 2014, influenza is responsible for substantial morbidity and mortality, with an average of over 100,000 hospitalizations and around 20,000 deaths, annually in the U.S.

Asia Pacific plant-based vaccines market is expected to show significant growth during the forecast period, owing to increasing number of collaborations and acquisitions between key players in the region. For instance, in 2013, Japan-based pharmaceutical company—Mitsubishi Tanabe Pharma Corporation—acquired Medicago Inc., a Canada-based biopharmaceutical company, focused on development of new plant-based vaccines. Furthermore, Mitsubishi Tanabe Pharma Corporation acquired 60% share of Medicago Inc. at total amount of US$ 357 million. The other 40% share is owned by an investment group, Philip Morris Investments B.V.

Else place an Inquire before Purchase “Plant-based Vaccines Market Size, Status and Forecast 2026 : https://www.coherentmarketinsights.com/insight/talk-to-analyst/2004

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.